. "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease"@en . . . . . "1"^^ . "11140" . "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease"@cs . "1555-9041" . "6" . . . "[328905D669D8]" . "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease"@en . . "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease" . . . . . "1" . "RIV/00216208:11140/06:00000608!RIV08-MSM-11140___" . "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease"@cs . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . . "1211;1215" . "Clinical Journal of the American Society of Nephrology" . "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease" . "5"^^ . "491940" . . . . . "C.E.R.A. has been shown to have a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with chronic kidney disease." . . "Opatrn\u00E1, Sylvie" . . . "RIV/00216208:11140/06:00000608" . "C.E.R.A. has been shown to have a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with chronic kidney disease."@cs . "V" . . "8"^^ . "C.E.R.A. has been shown to have a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with chronic kidney disease."@en . "Pharmacokinetics; pharmacodynamics; intravenous; subcutaneous; continuous; erythropoietin; receptor; activator; patients; chronic; kidney; disease"@en . .